<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>regulatory scrutiny on FinanClub</title>
    <link>https://finan.club/tags/regulatory-scrutiny/</link>
    <description>Recent content in regulatory scrutiny on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 22 Mar 2024 09:05:43 +0000</lastBuildDate><atom:link href="https://finan.club/tags/regulatory-scrutiny/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Fri, 22 Mar 2024 09:05:43 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:73
Chances: AstraZeneca&amp;rsquo;s acquisition of Fusion Biopharma for $21 per share in cash, along with a contingent value right of $3 per share, indicates strategic growth and expansion in the pharmaceutical industry. GSK&amp;rsquo;s plan to lower the prices of its inhaled respiratory products to $35 per month in the US in 2025 could lead to increased market share and customer loyalty.</description>
    </item>
    
    <item>
      <title>TSLA</title>
      <link>https://finan.club/us/tsla/</link>
      <pubDate>Tue, 12 Dec 2023 14:42:28 +0000</pubDate>
      
      <guid>https://finan.club/us/tsla/</guid>
      <description>score:85
Chances: Tesla&amp;rsquo;s expansion into energy generation and storage systems presents a significant opportunity for growth and diversification. Despite declining vehicle insurance registrations in China, Tesla is still aiming for record-setting quarterly deliveries and a strong year overall. The company&amp;rsquo;s ability to save lives and prevent injuries with its Autopilot technology provides a positive outlook for its automotive segment.</description>
    </item>
    
  </channel>
</rss>
